Kyverna’s Miv-cel Meets All Primary and Secondary Endpoints in Stiff Person Syndrome Trial

• Kyverna Therapeutics announced publication in JAMA Neurology of registrational KYSA-8 trial results for miv-cel in stiff person syndrome.
• Results were previously presented at the American Academy of Neurology annual meeting in April 2026.
• A single dose improved mobility and disability, with all patients discontinuing chronic immunotherapies.
• Treatment was well tolerated, with no high-grade cytokine release syndrome or neurotoxicity, and no cases of immune effector cell-associated hemophagocytic syndrome.
• No therapies are currently approved for stiff person syndrome; miv-cel could become its first approved treatment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyverna Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611091100PRIMZONEFULLFEED9872191) on November 09, 2026, and is solely responsible for the information contained therein.